Due to the resistance of HNSCC cells to chimeric antigen receptor T cell (CAR-T cell) therapy, the Suzuki team tested IL-12 and PD-L1-incorporated CAdVEC (CAdVECIL12_PDL1) in combination with human epidermal growth factor receptor 2 (HER2)-specific CAR-T cells in a mice model. The gene discussed is ERBB2; the disease is head and neck squamous cell carcinoma.